Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
about
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patientsThe impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational studySite-Specific PEGylation of Therapeutic ProteinsThe impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsEngineering long shelf life multi-layer biologically active surfaces on microfluidic devices for point of care applicationsChemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialSynthesis and antimicrobial activity of ciprofloxacin and norfloxacin permanently bonded to polyethylene glycol by a thiourea linker.Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Management of neutropenia in cancer patients.Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisA randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignanciesPegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplantEffectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapyClinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropeniaPharmacokinetics of pegfilgrastim.Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.Neutrophil biology and the next generation of myeloid growth factors.Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer.Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.The colony-stimulating factors and cancer.Dose density in adjuvant chemotherapy for breast cancer.Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and DocetaxelCanadian supportive care recommendations for the management of neutropenia in patients with cancer.Pharmacokinetic consequences of pegylation.A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
P2860
Q24632145-6C8B58D2-30E5-4EB4-AF1D-4CB93B28F296Q24804447-021F5E80-9483-40FE-9E62-DCB55C0E7C5FQ26777819-681D0A20-735E-458A-AA2C-895C6DE5684EQ27008080-15A12F8D-02E8-4ECA-B641-882C27F6B623Q30390401-FED85D81-269B-4823-AEB5-77C6E9D2716AQ30975418-BD086541-015C-4DE9-A729-5E2F774507D1Q33350688-3CDBA518-3DDA-4633-A3BE-70C0233C15B5Q33400268-8F9AB43A-CA7F-4A22-87C4-AC3DDFB33FAEQ33414659-E3DCB272-3305-4C05-8F27-E161E53F621AQ33602351-AE90D3FF-09A2-4A0C-8596-AC62702EE273Q33756369-478B1001-3B5C-444E-B520-6F8E589DEC34Q33762775-373810BC-97FE-48BB-BB67-15E41BC8744AQ33846178-AB8B4F3E-40F1-4041-A377-1B563FE64794Q34029496-9EF53747-AE9D-4959-A698-33888328049FQ34333814-BA3EC45A-7345-4558-8568-B582AB1F8FE1Q34343470-DB95B086-1ABF-4B38-9422-672522E7296AQ34353567-EE990F99-32A8-469D-86EF-9A23F47A2746Q34539360-47B9C35E-AD8E-4F99-AB82-3BA05AD819EDQ34544831-9AFC2B24-7E01-4076-8CE9-479ABD644EEEQ34553998-14FC90B6-F8BE-4325-A815-13A19A83A05FQ34620664-7A1875CE-3E95-4756-B345-50389580A5E8Q34941030-A9AC42CA-9147-42EC-BC4A-6737F76664C5Q35048703-1DAF7B6D-A8BD-45A6-BFB5-6FF48C113B58Q35200820-6DDD0526-0A0A-47E1-B8A1-2B74914032E1Q35200824-8FF3EA6C-9747-467D-965E-F8F5D3019DB5Q35303471-1334261E-7736-403C-B202-30FE8A726131Q35653712-653DC3E4-2AC4-4296-95A9-4F9C05D339BEQ35808451-7C43C2C9-84D4-43E2-8DE3-A12934101178Q35811836-35288F14-034C-4C9C-946E-CFE6DD5453D2Q35860879-475CED87-8E57-4D9B-B9BB-0D56E1A18389Q35936937-9FA54C78-3D11-4BD8-BE30-6B747EC6B5BCQ35964407-85F475F7-FCD5-4F95-A766-8179DE8311D7Q36000209-5951311E-DCB9-4D6D-A666-863977A248DAQ36004954-DA666DFE-572A-44FF-B69B-BC644261680BQ36103329-8B89E1A0-F32B-4FF1-9D28-39AB303AF274Q36235531-FDDDAE7D-49E8-467E-A768-ACF0E9CB2DC2Q36452230-458834DB-B087-4C21-A158-675017EAAD68Q36485208-9397BD6E-DD71-48AF-887B-8E5523BA58FCQ36604526-D6096FCE-37A1-466E-ADC0-B48BEE8A4002Q36615056-F607AA26-DE31-4DB0-94D2-FC97631C0527
P2860
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Blinded, randomized, multicent ...... or stage III/IV breast cancer.
@en
Blinded, randomized, multicent ...... or stage III/IV breast cancer.
@nl
type
label
Blinded, randomized, multicent ...... or stage III/IV breast cancer.
@en
Blinded, randomized, multicent ...... or stage III/IV breast cancer.
@nl
prefLabel
Blinded, randomized, multicent ...... or stage III/IV breast cancer.
@en
Blinded, randomized, multicent ...... or stage III/IV breast cancer.
@nl
P2093
P356
P1476
Blinded, randomized, multicent ...... or stage III/IV breast cancer.
@en
P2093
F A Holmes
I Wiznitzer
J A O'Shaughnessy
P304
P356
10.1200/JCO.20.3.727
P407
P577
2002-02-01T00:00:00Z